Povidone Iodine Nasal Application to Prevent Intraoperative Spread of SARS-CoV-2
SARS-CoV-2 Acute Respiratory Disease
About this trial
This is an interventional prevention trial for SARS-CoV-2 Acute Respiratory Disease focused on measuring General anesthetic, povidone iodine, transmission, infectivity
Eligibility Criteria
Inclusion Criteria: Adult patients Undergoing surgery (elective, urgent, or emergent) Requiring general anesthesia Acutely infected (<= 10 days from diagnosis) with SARS-CoV-2 Exclusion Criteria: Not general anesthesia Not acutely infected (<= 10 days from diagnosis) with SARS-CoV-2 Allergy to povidone iodine Unable to provide consent Pregnant individuals
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Povidone Iodine
Usual Care
5% povidone iodine will be swabbed in patients' nares (experimental group), one in each nostril, twice before incision.
Half of the patients will not receive 5% povidone iodine and will proceed with usual care.